300 related articles for article (PubMed ID: 18035221)
1. In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. (Int j radiat oncol biol phys 2007;67:651-659).
Messerschmidt GL; Oleka N
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651-2; author reply 1652. PubMed ID: 18035221
[No Abstract] [Full Text] [Related]
2. In regards to Münter et Al. (Int J Radiat Oncol Biol Phys 2007;67:651-659).
Samuels MA
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):318; author reply 318-9. PubMed ID: 17707287
[No Abstract] [Full Text] [Related]
3. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
[TBL] [Abstract][Full Text] [Related]
4. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
Rudat V; Münter M; Rades D; Grötz KA; Bajrovic A; Haberkorn U; Brenner W; Debus J
Radiother Oncol; 2008 Oct; 89(1):71-80. PubMed ID: 18707782
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology and management of radiation-induced xerostomia.
Berk LB; Shivnani AT; Small W
J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
[TBL] [Abstract][Full Text] [Related]
7. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
8. [Current status of prevention and management of radiation-induced xerostomia].
Ma DY; Qiu WL; Zhang CP
Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
[No Abstract] [Full Text] [Related]
9. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiation therapy and xerostomia.
Chambers MS; Weber RS; Garden AS
J Calif Dent Assoc; 2006 Sep; 34(9):743-8. PubMed ID: 17022299
[TBL] [Abstract][Full Text] [Related]
11. Scintigraphy in prediction of the salivary gland function after gland-sparing intensity modulated radiation therapy for head and neck cancer.
Tenhunen M; Collan J; Kouri M; Kangasmäki A; Heikkonen J; Kairemo K; Mäkitie A; Joensuu H; Saarilahti K
Radiother Oncol; 2008 May; 87(2):260-7. PubMed ID: 18329118
[TBL] [Abstract][Full Text] [Related]
12. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
[TBL] [Abstract][Full Text] [Related]
13. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy-induced salivary dysfunction.
Ship JA; Hu K
Semin Oncol; 2004 Dec; 31(6 Suppl 18):29-36. PubMed ID: 15726520
[TBL] [Abstract][Full Text] [Related]
15. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
Chao KS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
[TBL] [Abstract][Full Text] [Related]
16. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
de Castro G; Federico MH
Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
[TBL] [Abstract][Full Text] [Related]
17. New approaches to preventing xerostomia.
J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
[No Abstract] [Full Text] [Related]
18. Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumours.
Liem IH; Olmos RA; Balm AJ; Keus RB; van Tinteren H; Takes RP; Muller SH; Bruce AM; Hoefnagel CA; Hilgers FJ
Eur J Nucl Med; 1996 Nov; 23(11):1485-90. PubMed ID: 8854847
[TBL] [Abstract][Full Text] [Related]
19. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
20. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
